TARSUS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
TARSUS PHARMACEUTICALS, INC. (TARS) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $49.57 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $49.57.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $47.13.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $34.46.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $32.71.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $49.57 10-Q · filed 2026-08-06 |
| 2026-03-31 | $47.13 10-Q · filed 2026-05-06 |
| 2025-12-31 | $34.46 10-K · filed 2026-02-23 |
| 2025-09-30 | $32.71 10-Q · filed 2025-11-04 |
| 2025-06-30 | $31.31 10-Q · filed 2025-08-06 |
| 2025-03-31 | $30.16 10-Q · filed 2025-05-01 |
| 2024-12-31 | $25.64 10-K · filed 2025-02-25 |
| 2024-09-30 | $24.62 10-Q · filed 2024-11-13 |
| 2024-06-30 | $24.14 10-Q · filed 2024-08-08 |
| 2024-03-31 | $23.22 10-Q · filed 2024-05-08 |
| 2023-12-31 | $18.45 10-K · filed 2024-02-27 |
| 2023-09-30 | $18.33 10-Q · filed 2023-11-09 |
| 2023-06-30 | $18.00 10-Q · filed 2023-08-10 |
| 2023-03-31 | $18.15 10-Q · filed 2023-05-09 |
| 2022-12-31 | $19.12 10-K · filed 2023-03-17 |
| 2021-12-31 | $20.75 10-K · filed 2022-03-14 |
| 2020-12-31 | $4.41 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |